<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4424</id>
  <title>T3D4370</title>
  <common-name>L-Valine</common-name>
  <description>Valine (abbreviated as Val or V) is an -amino acid with the chemical formula HO2CCH(NH2)CH(CH3)2. It is named after the plant valerian. L-Valine is one of 20 proteinogenic amino acids. Its codons are GUU, GUC, GUA, and GUG. This essential amino acid is classified as nonpolar. Along with leucine and isoleucine, valine is a branched-chain amino acid. Branched chain amino acids (BCAA) are essential amino acids whose carbon structure is marked by a branch point. These three amino acids are critical to human life and are particularly involved in stress, energy and muscle metabolism. BCAA supplementation as therapy, both oral and intravenous, in human health and disease holds great promise. BCAA denotes valine, isoleucine and leucine which are branched chain essential amino acids. Despite their structural similarities, the branched amino acids have different metabolic routes, with valine going solely to carbohydrates, leucine solely to fats and isoleucine to both. The different metabolism accounts for different requirements for these essential amino acids in humans: 12 mg/kg, 14 mg/kg and 16 mg/kg of valine, leucine and isoleucine respectively. Furthermore, these amino acids have different deficiency symptoms. Valine deficiency is marked by neurological defects in the brain, while isoleucine deficiency is marked by muscle tremors. Many types of inborn errors of BCAA metabolism exist, and are marked by various abnormalities. The most common form is the maple syrup urine disease, marked by a characteristic urinary odor. Other abnormalities are associated with a wide range of symptoms, such as mental retardation, ataxia, hypoglycemia, spinal muscle atrophy, rash, vomiting and excessive muscle movement. Most forms of BCAA metabolism errors are corrected by dietary restriction of BCAA and at least one form is correctable by supplementation with 10 mg of biotin daily. BCAA are decreased in patients with liver disease, such as hepatitis, hepatic coma, cirrhosis, extrahepatic biliary atresia or portacaval shunt; aromatic amino acids (AAA) tyrosine, tryptophan and phenylalanine, as well as methionine are increased in these conditions. Valine in particular, has been established as a useful supplemental therapy to the ailing liver. All the BCAA probably compete with AAA for absorption into the brain. Supplemental BCAA with vitamin B6 and zinc help normalize the BCAA:AAA ratio.  In sickle-cell disease, valine substitutes for the hydrophilic amino acid glutamic acid in hemoglobin. Because valine is hydrophobic, the hemoglobin does not fold correctly. Valine is an essential amino acid, hence it must be ingested, usually as a component of proteins.</description>
  <cas>72-18-4</cas>
  <pubchem-id>6287</pubchem-id>
  <chemical-formula>C5H11NO2</chemical-formula>
  <weight>117.15</weight>
  <appearance>White powder.</appearance>
  <melting-point>315°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>5.85E+004 mg/L (at 25°C)</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Absorbed from the small intestine by a sodium-dependent active-transport process.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>(Applies to Valine, Leucine and Isoleucine) &lt;br/&gt;This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. &lt;br/&gt;The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. &lt;br/&gt;There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.</mechanism-of-toxicity>
  <metabolism>Hepatic</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Promotes mental vigor, muscle coordination, and calm emotions. May also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms>Symptoms of hypoglycemia.</symptoms>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:35:54Z</created-at>
  <updated-at type="dateTime">2026-05-14T16:24:22Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>valine</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00183</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>16414</chebi-id>
  <biocyc-id>VAL</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB00161</drugbank-id>
  <pdb-id>VAL</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC(C)[C@H](N)C(O)=O</moldb-smiles>
  <moldb-formula>C5H11NO2</moldb-formula>
  <moldb-inchi>InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1</moldb-inchi>
  <moldb-inchikey>KZSNJWFQEVHDMF-BYPYZUCNSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">117.1463</moldb-average-mass>
  <moldb-mono-mass type="decimal">117.078978601</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-2.26</logp>
  <hmdb-id>HMDB00883</hmdb-id>
  <chembl-id>CHEMBL43068</chembl-id>
  <chemspider-id>6050</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Hiroshi Matsui, Takayasu Tsuchida, Shigeru Nakamori, &amp;#8220;Method for producing L-valine by fermentation.&amp;#8221; U.S. Patent US4391907, issued July, 1981.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003330</chemdb-id>
  <dsstox-id>DTXSID40883233</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00107590</susdat-id>
  <iupac>(2S)-2-amino-3-methylbutanoic acid</iupac>
  <moldb-polar-surface-area>63.31999999999999</moldb-polar-surface-area>
  <moldb-refractivity>29.4929</moldb-refractivity>
  <moldb-polarizability>12.191412403732404</moldb-polarizability>
  <moldb-rotatable-bond-count>2</moldb-rotatable-bond-count>
  <moldb-acceptor-count>3</moldb-acceptor-count>
  <moldb-donor-count>2</moldb-donor-count>
  <moldb-pka-strongest-acidic>2.7172733818557755</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>9.599176382928611</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>0</moldb-number-of-rings>
  <moldb-alogps-logp>-2.29</moldb-alogps-logp>
  <moldb-alogps-logs>0.26</moldb-alogps-logs>
  <moldb-alogps-solubility>2.14e+02 g/l</moldb-alogps-solubility>
</compound>
